Atria Wealth Solutions Inc. lessened its holdings in Danaher Co. (NYSE:DHR – Free Report) by 11.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 21,337 shares of the conglomerate’s stock after selling 2,720 shares during the period. Atria Wealth Solutions Inc.’s holdings in Danaher were worth $4,900,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of DHR. AMF Tjanstepension AB purchased a new stake in shares of Danaher in the 3rd quarter worth approximately $5,923,000. Howard Capital Management Group LLC increased its stake in Danaher by 4.1% during the 3rd quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 48 shares in the last quarter. Foundations Investment Advisors LLC increased its stake in Danaher by 5.3% during the 3rd quarter. Foundations Investment Advisors LLC now owns 1,637 shares of the conglomerate’s stock valued at $455,000 after purchasing an additional 82 shares in the last quarter. Oakworth Capital Inc. increased its stake in Danaher by 14.2% during the 3rd quarter. Oakworth Capital Inc. now owns 523 shares of the conglomerate’s stock valued at $145,000 after purchasing an additional 65 shares in the last quarter. Finally, Sequoia Financial Advisors LLC increased its stake in Danaher by 7.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 20,803 shares of the conglomerate’s stock valued at $5,784,000 after purchasing an additional 1,527 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Insider Activity
In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.90% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on Danaher
Danaher Stock Performance
DHR opened at $205.23 on Thursday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The company has a market cap of $148.24 billion, a price-to-earnings ratio of 38.87, a PEG ratio of 2.63 and a beta of 0.83. Danaher Co. has a 52-week low of $196.80 and a 52-week high of $281.70. The firm’s fifty day simple moving average is $227.74 and its two-hundred day simple moving average is $247.80.
Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the business earned $2.09 EPS. Equities analysts anticipate that Danaher Co. will post 7.67 earnings per share for the current fiscal year.
Danaher Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.53%. The ex-dividend date was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.45%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
- Five stocks we like better than Danaher
- High Flyers: 3 Natural Gas Stocks for March 2022
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- Where Do I Find 52-Week Highs and Lows?
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- What is the Euro STOXX 50 Index?
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.